Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Scurries To Prepare For PDUFA: Currie Moves Up To Chief Lobbyist

Executive Summary

PhRMA's federal lobbying efforts heading into the Prescription Drug User Fee Act reauthorization deliberations will be led by one of the key staffers during the 1997 FDA Modernization Act debate.

You may also be interested in...



BIO Preparing For Human Subject Protection Provisions In FDA Bills

The Biotechnology Industry Organization is preparing for the inclusion of human subject protection provisions in FDA bills scheduled for action in 2002.

Amgen Working With Sen. Kennedy On Medicare Rx Benefit Bill

Amgen is working with the ranking Democrat on the Senate Health Committee, Sen. Kennedy (D-Mass.), to develop a Medicare prescription drug benefit bill.

PhRMA Seeking New Chief Lobbyist; Christy To Leave Association This Spring

PhRMA is seeking a new chief lobbyist to replace Senior VP-Federal Affairs James Christy, who is leaving the association in two months.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel